Drug Profile
WX 037
Alternative Names: WX-037Latest Information Update: 16 Oct 2015
Price :
$50
*
At a glance
- Originator UCB Pharma SA
- Developer WILEX AG
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Apr 2014 Discontinued - Phase-I for Solid tumours (combination therapy) in United Kingdom (PO)
- 11 Jul 2013 Phase-I clinical trials in Solid tumours (combination therapy) in United Kingdom (PO)